Plain-English translation of NCT07784387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Urinary Bladder Neoplasms research guide →This is a research study that looks back at medical records of people in Portugal who were diagnosed with high-risk, early-stage bladder cancer between 2016 and 2020. Researchers want to understand how doctors currently treat this type of cancer in everyday practice — what tests they use, what treatments they recommend, and how patients do over time. No new medication or treatment is being tested; instead, researchers are learning from real-world care that already happened.
High-risk early-stage bladder cancer has a significant chance of coming back or getting worse, so doctors need better information about which treatments work best and how to care for patients over the long term. This study aims to understand current treatment patterns in Portugal so that care can be improved.
You likely qualify if…
You likely don't qualify if…
You will not need to visit a clinic or take any medication for this study. Researchers will simply review your existing medical records — both electronic and paper — from your diagnosis until at least 5 years later. They will collect information about how you were diagnosed, what treatments you received, and how your cancer progressed over time. Your involvement is passive: the study team gathers and analyzes your routine care information.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
Portugal
Sponsor
Janssen-Cilag Farmaceutica Ltda.
Enrollment target
~250 participants
Started
August 2026
Primary completion
February 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Contact
Janssen-Cilag Farmaceutica Ltda.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.